Proof-of-principle Phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer: safety, feasibility, and exploratory analysis-Reference-Cited by-同舟云学术

Proof-of-principle Phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer: safety, feasibility, and exploratory analysis

Published:2020-07-10 Issue:1 Volume:24 Page:140-149
ISSN:1365-7852
Container-title:Prostate Cancer and Prostatic Diseases
language:en
Short-container-title:Prostate Cancer Prostatic Dis

Author:

Yuan Zhigang,Fernandez Daniel,Dhillon Jasreman,Abraham-Miranda Julieta,Awasthi Shivanshu,Kim Youngchul,Zhang Jingsong,Jain Rohit,Serna Amparo,Pow-Sang Julio M.,Poch Michael,Li Roger^ORCID,Manley Brandon,Fink Angelina,Naghavi Arash,Torres-Roca Javier F.,Grass G. Daniel,Kim Sungjune,Latifi Kujtim,Hunt Dylan,Johnstone Peter A. S.,Yamoah Kosj

Funder

Bristol-Myers Squibb

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Urology,Oncology

Link

http://www.nature.com/articles/s41391-020-0254-y.pdf

Reference36 articles.

1. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl J Med. 2017;377:1345–56.

2. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl J Med. 2015;372:2018–28.

3. Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl J Med. 2018;378:1277–90.